Vaxart (Vaxart) EBIT per Share : $-0.53 (TTM As of Mar. 2024)

View and export this data going back to 1990. Start your Free Trial

What is Vaxart EBIT per Share?

Vaxart's EBIT per Share for the three months ended in Mar. 2024 was $-0.14. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.53.

During the past 3 years, the average EBIT per Share Growth Rate was -18.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was 16.60% per year. During the past 10 years, the average EBIT per Share Growth Rate was 25.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Vaxart's EBIT per Share or its related term are showing as below:

VXRT' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -30.1 Med: 25.5 Max: 67.5
Current: -18

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Vaxart was 67.50% per year. The lowest was -30.10% per year. And the median was 25.50% per year.

VXRT's 3-Year EBIT Growth Rate is ranked worse than
73.1% of 1305 companies
in the Biotechnology industry
Industry Median: 3.4 vs VXRT: -18.00

Vaxart's EBIT for the three months ended in Mar. 2024 was $-23.57 Mil.

Vaxart EBIT per Share Historical Data

The historical data trend for Vaxart's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart EBIT per Share Chart

Vaxart Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.73

-0.34

-0.57

-0.83

-0.56

Vaxart Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.18	-0.16	-0.11	-0.12	-0.14

Vaxart EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Vaxart's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-80.757	/	144.820
=	-0.56

Vaxart's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-23.568	/	168.811
=	-0.14

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.53

Vaxart (NAS:VXRT) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Vaxart EBIT per Share Related Terms

Thank you for viewing the detailed overview of Vaxart's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxart (Vaxart) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (NAS:VXRT) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

NB11:Germany NB11:Germany

Address

170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.vaxart.com

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Executives

W. Mark Watson	director	324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Phillip E Lee	officer: Chief Financial Officer	C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Elaine J Heron	director	6 STONEGATE RD, PONTOLA VALLEY CA 94028
Fuad Ahmad	officer: Interim CFO	461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Edward B Berg	officer: SVP, General Counsel	C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Robert A. Yedid	director	C/O LIFESCI ADVISORS, 250 WEST 55TH STREET, SUITE 3401, NEW YORK NY 10019
Margaret Echerd	officer: VP, Corporate Controller, PAO	3585 MONROE STREET, SANTA CLARA CA 95051
James F. Cummings	officer: Chief Medical Officer	1312 BEACHVIEW ROAD, ANNAPOLIS MD 21403
Julie M Cherrington	director	9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Sean Tucker	officer: Chief Scientific Officer	385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
Wouter Latour	director, officer: President and Chief Executive	385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
David E. Wheadon	director	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Karen J Wilson	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Todd C Davis	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037